Triopsy Management Team
David G. Bostwick, MD, MBA, FCAP
Chief Executive Officer
Our visionary CEO brings over four decades of expertise in prostate cancer, bladder cancer, and urologic diseases. A former Mayo Clinic professor, he's internationally renowned, delivering 2,000+ lectures worldwide and publishing 25+ book chapters, 450+ papers, and 17 books, including the best-selling uropathology textbook Urologic Surgical Pathology. Dr. Bostwick is a luminary in uropathology. He continues to shape the field by serving on the editorial boards of 10 medical journals.
Brad J. Buscher
Executive Chairman of the Board
Mr. Buscher, a highly experienced merchant banker, has been integral to Triopsy since 2015, spearheading product development, engineering, FDA approvals, IP strategy, reimbursement plans, and capital procurement. With a wealth of experience in healthcare start-up investments and nurturing early-stage enterprises, his leadership has been pivotal in driving Triopsy's innovation and growth. Mr. Buscher's multifaceted expertise is a cornerstone of Triopsy's mission to revolutionize medical diagnostics.
Paul Arangua, MPH
Director of Research and Product Development
With more than 14 years of clinical experience, Mr. Arangua is an experienced public health professional specializing in prostate cancer. Over the past 8+ years, he has led pioneering efforts in 3D diagnostics and targeted focal therapy for prostate cancer. Mr. Arangua excels in designing, marketing, implementing, and evaluating programs related to genomics, screening, diagnostic tools, and clinical epidemiology for both benign and malignant prostate conditions.
For additional information, please fill out the form below.
For more information, please contact
Brad J. Buscher
Executive Chairman of the Board
bbuscher@triopsy.com